Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo
- PMID:14985453
Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo
Abstract
Glioblastoma is a therapeutic challenge as a highly infiltrative, proliferative, and resistant tumor. Among novel therapeutic approaches, proteasome inhibition is very promising in controlling cell cycle and inducing apoptosis. This study investigated the effect of ritonavir, a protease inhibitor of the HIV and a proteasome modulator, on glioma cells. The hypothesis was that proteasome modulation, mainly by only inhibiting proteasome chymotrypsin-like activity, could be sufficient to control tumor progression. The experiments were done on a human glioblastoma-derived GL15 cell line and a rat nitrosourea-induced gliosarcoma 9L cell line. Culturing conditions included monolayer cultures, transplantations into brain slices, and transplantations into rat striata. The study demonstrates that ritonavir, by inhibiting the chymotrypsin-like activity of the proteasome, has cytostatic and cytotoxic effects on glioma cells, and can induce resistances in vitro. Ritonavir was unable to control tumor growth in vivo, likely because the therapeutic dose was not reached in the tumor in vivo. Nevertheless, ritonavir might also be beneficial, by decreasing tumor infiltration, in the reduction of the deleterious peritumor edema in glioblastoma.
Similar articles
- Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.Gaedicke S, Firat-Geier E, Constantiniu O, Lucchiari-Hartz M, Freudenberg M, Galanos C, Niedermann G.Gaedicke S, et al.Cancer Res. 2002 Dec 1;62(23):6901-8.Cancer Res. 2002.PMID:12460905
- Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.Hosseini H, André P, Lefevre N, Viala L, Walzer T, Peschanski M, Lotteau V.Hosseini H, et al.J Neuroimmunol. 2001 Aug 30;118(2):233-44. doi: 10.1016/s0165-5728(01)00352-6.J Neuroimmunol. 2001.PMID:11498258
- Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells.Wagenknecht B, Hermisson M, Eitel K, Weller M.Wagenknecht B, et al.Cell Physiol Biochem. 1999;9(3):117-25. doi: 10.1159/000016308.Cell Physiol Biochem. 1999.PMID:10494025
- How an inhibitor of the HIV-I protease modulates proteasome activity.Schmidtke G, Holzhütter HG, Bogyo M, Kairies N, Groll M, de Giuli R, Emch S, Groettrup M.Schmidtke G, et al.J Biol Chem. 1999 Dec 10;274(50):35734-40. doi: 10.1074/jbc.274.50.35734.J Biol Chem. 1999.PMID:10585454
- Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.Kraus M, Müller-Ide H, Rückrich T, Bader J, Overkleeft H, Driessen C.Kraus M, et al.Leuk Res. 2014 Mar;38(3):383-92. doi: 10.1016/j.leukres.2013.12.017. Epub 2013 Dec 25.Leuk Res. 2014.PMID:24418752
Cited by
- Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.Yu C, Friday BB, Yang L, Atadja P, Wigle D, Sarkaria J, Adjei AA.Yu C, et al.Neuro Oncol. 2008 Jun;10(3):309-19. doi: 10.1215/15228517-2007-063. Epub 2008 Apr 29.Neuro Oncol. 2008.PMID:18445700Free PMC article.
- α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells.Bazzaro M, Anchoori RK, Mudiam MK, Issaenko O, Kumar S, Karanam B, Lin Z, Isaksson Vogel R, Gavioli R, Destro F, Ferretti V, Roden RB, Khan SR.Bazzaro M, et al.J Med Chem. 2011 Jan 27;54(2):449-56. doi: 10.1021/jm100589p. Epub 2010 Dec 27.J Med Chem. 2011.PMID:21186794Free PMC article.
- A Strategy Utilizing Protein-Protein Interaction Hubs for the Treatment of Cancer Diseases.Carels N, Sgariglia D, Junior MGV, Lima CR, Carneiro FRG, Silva GFD, Silva FABD, Scardini R, Tuszynski JA, Andrade CV, Monteiro AC, Martins MG, Silva TGD, Ferraz H, Finotelli PV, Balbino TA, Pinto JC.Carels N, et al.Int J Mol Sci. 2023 Nov 8;24(22):16098. doi: 10.3390/ijms242216098.Int J Mol Sci. 2023.PMID:38003288Free PMC article.Review.
- Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.Kast RE, Ramiro S, Lladó S, Toro S, Coveñas R, Muñoz M.Kast RE, et al.J Neurooncol. 2016 Feb;126(3):425-31. doi: 10.1007/s11060-015-1996-6. Epub 2015 Nov 24.J Neurooncol. 2016.PMID:26603162
- Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.Azzalin A, Nato G, Parmigiani E, Garello F, Buffo A, Magrassi L.Azzalin A, et al.Neoplasia. 2017 Apr;19(4):364-373. doi: 10.1016/j.neo.2017.02.009. Epub 2017 Mar 19.Neoplasia. 2017.PMID:28319810Free PMC article.
MeSH terms
Substances
Related information
LinkOut - more resources
Other Literature Sources